Orexin Receptor
The orexins, also known as hypocretins, are a pair of neuropeptides that are mainly derived from orexin-containing neurons in the lateral hypothalamus (LH). Orexin-A (OA; hypocretin-1) and orexin-B (OB; hypocretin-2) are closely related small peptides that are widely distributed throughout the central and peripheral nervous systems. Orexins stimulate food intake upon intracerebroventricular administration, and were originally described as regulators of feeding behavior. Subsequent experiments revealed many other important physiological functions of these peptides, including regulation of the sleep–wake cycle, energy homeostasis (Tsuneki et al., 2012), neuroendocrine functions, glucose metabolism, stress-adaptive responses and reward-seeking and drug addiction.
Orexins bind their cognate G-protein–coupled receptors (GPCRs), orexin receptor type 1 (OX1R, also named as Hcrtr-1) and type 2 (OX2R, or Hcrtr-2), which activate different downstream signal pathways, thereby exerting a variety of physiological functions. Orexin and orexin receptors are ectopically expressed in many diseases, especially neurological disorders, suggesting that the orexin/receptor pathway plays critical roles in the pathology and pathogenesis of these illnesses. OA and OB orchestrate their diverse effects by binding and activating two GPCRs, OX1R and OX2R. The mRNAs of human OX1R and OX2R are 1564 and 1843 bp in length, respectively, and are translated into proteins of 425 and 444 aa. OX1R and OX2R share 64% amino acid identity. Rat OX1R and OX2R mRNAs are 2469 and 3114 bp in length, respectively, and encode proteins of 413 and 460 aa. Human and rat OX1R and OX2R share 94% and 95% identity, indicating that the orexin receptor is highly conserved among mammals.
Calcium is a very important second messenger of GPCR-mediated signaling. Previous studies demonstrated that orexin treatment significantly increases the intracellular Ca2+ concentration ([Ca2+]i) in cells overexpressing OX1R and OX2R, an effect that is mainly triggered by activation of the classical phospholipase C (PLC) cascade (PLC-IP3/DAG). Subsequent work showed that OA acts on OX1R, which in turn activates transient receptor potential channel 3 (TRPC3), thereby triggering Ca2+ responses.Other orexin/receptor signaling pathways have also been reported, including the phospholipase D (PLD)/phosphatidic acid (PA), phospholipase A (PLA)/arachidonic acid (AA), and mitogen-activated protein kinase (MAPK) cascades. Orexins also activate p38-MAPK signaling pathway and increase the level of phosphorylated ERK1/2 in a dose- and time-dependent manner in both cell lines and tissues. ERK1/2 activation induced by orexins involves Gq/PLC/PKC signaling, but not the PKA pathway. In addition, OA affects rat insulinoma cell proliferation via stimulation of the AKT signaling pathway by OX1R.
References
1.Wang C, et al. Front Mol Neurosci. 2018;11:220.
Orexins bind their cognate G-protein–coupled receptors (GPCRs), orexin receptor type 1 (OX1R, also named as Hcrtr-1) and type 2 (OX2R, or Hcrtr-2), which activate different downstream signal pathways, thereby exerting a variety of physiological functions. Orexin and orexin receptors are ectopically expressed in many diseases, especially neurological disorders, suggesting that the orexin/receptor pathway plays critical roles in the pathology and pathogenesis of these illnesses. OA and OB orchestrate their diverse effects by binding and activating two GPCRs, OX1R and OX2R. The mRNAs of human OX1R and OX2R are 1564 and 1843 bp in length, respectively, and are translated into proteins of 425 and 444 aa. OX1R and OX2R share 64% amino acid identity. Rat OX1R and OX2R mRNAs are 2469 and 3114 bp in length, respectively, and encode proteins of 413 and 460 aa. Human and rat OX1R and OX2R share 94% and 95% identity, indicating that the orexin receptor is highly conserved among mammals.
Calcium is a very important second messenger of GPCR-mediated signaling. Previous studies demonstrated that orexin treatment significantly increases the intracellular Ca2+ concentration ([Ca2+]i) in cells overexpressing OX1R and OX2R, an effect that is mainly triggered by activation of the classical phospholipase C (PLC) cascade (PLC-IP3/DAG). Subsequent work showed that OA acts on OX1R, which in turn activates transient receptor potential channel 3 (TRPC3), thereby triggering Ca2+ responses.Other orexin/receptor signaling pathways have also been reported, including the phospholipase D (PLD)/phosphatidic acid (PA), phospholipase A (PLA)/arachidonic acid (AA), and mitogen-activated protein kinase (MAPK) cascades. Orexins also activate p38-MAPK signaling pathway and increase the level of phosphorylated ERK1/2 in a dose- and time-dependent manner in both cell lines and tissues. ERK1/2 activation induced by orexins involves Gq/PLC/PKC signaling, but not the PKA pathway. In addition, OA affects rat insulinoma cell proliferation via stimulation of the AKT signaling pathway by OX1R.
References
1.Wang C, et al. Front Mol Neurosci. 2018;11:220.
GPCR/G Protein
ACAT(3)
Angiotensin Receptor(27)
Antibacterial(471)
Bombesin Receptor(11)
Bradykinin Receptor(18)
Calcium Channel(137)
cAMP(9)
Cannabinoid Receptor(69)
CaSR(17)
CGRP Receptor(14)
Chemokine Receptor(104)
Cholecystokinin Receptor(17)
CRF Receptor(13)
Dopamine Receptor(145)
Endothelin Receptor(20)
FFAR(5)
Galanin Receptor(1)
GHSR(16)
Glucagon Receptor(36)
GPCR19(7)
GPR119(3)
Hedgehog (Hh)(27)
Histamine Receptor(110)
Imidazoline Receptor(1)
Leukotriene Receptor(9)
LHR(1)
LPA Receptor(12)
Lysophospholipid Receptor(13)
mAChR(25)
MCHR(6)
Melanocortin Receptor(22)
Melatonin Receptor(5)
mGluR(11)
Motilin Receptor(4)
Neurokinin Receptor(34)
Neuropeptide Y Receptor(36)
Neurotensin Receptor(8)
Orexin Receptor(14)
Other Targets(3)
OXTR(2)
P2Y Receptor(8)
PAR(24)
Platelet-activating Factor Receptor(2)
Prostaglandin Receptor(60)
PTH Receptor(1)
S1P Receptor(22)
SGLT(22)
Somatostatin Receptor(11)
Urotensin Receptor(4)
Vasopressin Receptor(16)
Orexin Receptor
-
[Ala11,D-Leu15]-Orexin B
catalog no : M30608
cas no: 532932-99-3
Highly potent and selective OX2 receptor agonist; displays 400-fold selectivity over OX1 receptors. EC50 values are 0.13 and 52 nM for human OX2 and OX1 receptors respectively. -
OXA (17-33)
catalog no : M30606
cas no: 343268-91-7
Potent and selective peptide orexin OX1 receptor agonist (EC50 values are 8.29 and 187 nM for OX1 and OX2 receptors respectively). Truncated form of orexin A. -
L-368,899 hydrochloride
catalog no : M21719
cas no: 160312-62-9
L-368,899 hydrochloride is a potent, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. -
Almorexant hydrochloride
catalog no : M16560
cas no: 913358-93-7
A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively. -
Almorexant
catalog no : M16329
cas no: 871224-64-5
A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively.